Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 50474 | 4.38 |
09:34 ET | 2525 | 4.4 |
09:36 ET | 23624 | 4.42 |
09:38 ET | 29474 | 4.41 |
09:39 ET | 3500 | 4.405 |
09:41 ET | 4380 | 4.405 |
09:43 ET | 8041 | 4.4 |
09:45 ET | 11501 | 4.395 |
09:48 ET | 13021 | 4.405 |
09:50 ET | 15127 | 4.395 |
09:52 ET | 14801 | 4.42 |
09:54 ET | 6830 | 4.41 |
09:56 ET | 2200 | 4.41 |
09:57 ET | 23949 | 4.405 |
09:59 ET | 36099 | 4.4 |
10:01 ET | 235179 | 4.4 |
10:03 ET | 39135 | 4.41 |
10:06 ET | 11522 | 4.415 |
10:08 ET | 23109 | 4.415 |
10:10 ET | 15302 | 4.415 |
10:12 ET | 17341 | 4.405 |
10:14 ET | 6849 | 4.4 |
10:15 ET | 16556 | 4.395 |
10:17 ET | 72000 | 4.38 |
10:19 ET | 10965 | 4.38 |
10:21 ET | 40690 | 4.4 |
10:24 ET | 27885 | 4.395 |
10:26 ET | 5664 | 4.395 |
10:28 ET | 20313 | 4.4 |
10:30 ET | 18375 | 4.395 |
10:32 ET | 13946 | 4.39 |
10:33 ET | 4249 | 4.3909 |
10:35 ET | 1200 | 4.395 |
10:37 ET | 3266 | 4.4 |
10:39 ET | 3600 | 4.395 |
10:42 ET | 8684 | 4.38 |
10:44 ET | 9928 | 4.37355 |
10:46 ET | 4267 | 4.37 |
10:48 ET | 4844 | 4.375 |
10:50 ET | 13372 | 4.375 |
10:51 ET | 15632 | 4.385 |
10:53 ET | 10139 | 4.395 |
10:55 ET | 10125 | 4.39 |
10:57 ET | 7418 | 4.395 |
11:00 ET | 199467 | 4.38 |
11:02 ET | 46861 | 4.37 |
11:04 ET | 349 | 4.375 |
11:06 ET | 3502 | 4.375 |
11:08 ET | 6023 | 4.38 |
11:09 ET | 11629 | 4.375 |
11:11 ET | 2817 | 4.38 |
11:13 ET | 5937 | 4.375 |
11:15 ET | 9559 | 4.3841 |
11:18 ET | 17938 | 4.3921 |
11:20 ET | 9566 | 4.3946 |
11:22 ET | 7844 | 4.395 |
11:24 ET | 5928 | 4.4 |
11:26 ET | 118919 | 4.395 |
11:27 ET | 177922 | 4.405 |
11:29 ET | 397846 | 4.485 |
11:31 ET | 276535 | 4.415 |
11:33 ET | 102360 | 4.415 |
11:36 ET | 29694 | 4.405 |
11:38 ET | 16431 | 4.405 |
11:40 ET | 32374 | 4.41 |
11:42 ET | 12608 | 4.4299 |
11:44 ET | 44823 | 4.435 |
11:45 ET | 9951 | 4.425 |
11:47 ET | 12250 | 4.43 |
11:49 ET | 38882 | 4.425 |
11:51 ET | 10422 | 4.43 |
11:54 ET | 88735 | 4.44 |
11:56 ET | 16277 | 4.435 |
11:58 ET | 3590 | 4.44 |
12:00 ET | 8530 | 4.435 |
12:02 ET | 11192 | 4.43 |
12:03 ET | 33690 | 4.41 |
12:05 ET | 19460 | 4.42 |
12:07 ET | 5202 | 4.415 |
12:09 ET | 27887 | 4.41 |
12:12 ET | 64802 | 4.38 |
12:14 ET | 4055 | 4.39 |
12:16 ET | 6108 | 4.39 |
12:18 ET | 7986 | 4.38 |
12:20 ET | 23421 | 4.385 |
12:21 ET | 10901 | 4.385 |
12:23 ET | 6563 | 4.385 |
12:25 ET | 11314 | 4.385 |
12:27 ET | 19116 | 4.385 |
12:30 ET | 10575 | 4.385 |
12:32 ET | 4233 | 4.38 |
12:34 ET | 93081 | 4.375 |
12:36 ET | 4180 | 4.37 |
12:38 ET | 15707 | 4.365 |
12:39 ET | 600 | 4.36 |
12:41 ET | 1200 | 4.36 |
12:43 ET | 12756 | 4.365 |
12:45 ET | 6441 | 4.35 |
12:48 ET | 4406 | 4.35 |
12:50 ET | 16579 | 4.345 |
12:52 ET | 54087 | 4.355 |
12:54 ET | 3414 | 4.35 |
12:56 ET | 29895 | 4.34 |
12:57 ET | 3750 | 4.34 |
12:59 ET | 17238 | 4.335 |
01:01 ET | 7304 | 4.32 |
01:03 ET | 19748 | 4.33 |
01:06 ET | 6389 | 4.3241 |
01:08 ET | 4991 | 4.325 |
01:10 ET | 7206 | 4.325 |
01:12 ET | 1350 | 4.325 |
01:14 ET | 19481 | 4.33 |
01:15 ET | 3363 | 4.325 |
01:17 ET | 29199 | 4.335 |
01:19 ET | 6413 | 4.335 |
01:21 ET | 12622 | 4.345 |
01:24 ET | 4691 | 4.35 |
01:26 ET | 41019 | 4.345 |
01:28 ET | 1960 | 4.345 |
01:30 ET | 12945 | 4.335 |
01:32 ET | 2218 | 4.335 |
01:33 ET | 4838 | 4.34 |
01:35 ET | 11063 | 4.345 |
01:37 ET | 9643 | 4.335 |
01:39 ET | 14985 | 4.335 |
01:42 ET | 13129 | 4.335 |
01:44 ET | 7978 | 4.335 |
01:46 ET | 13514 | 4.335 |
01:48 ET | 9210 | 4.345 |
01:50 ET | 22678 | 4.35 |
01:51 ET | 6682 | 4.355 |
01:53 ET | 15057 | 4.36 |
01:55 ET | 15093 | 4.36 |
01:57 ET | 3577 | 4.365 |
02:00 ET | 2654 | 4.37 |
02:02 ET | 10467 | 4.365 |
02:04 ET | 180022 | 4.365 |
02:06 ET | 105013 | 4.395 |
02:08 ET | 3805 | 4.395 |
02:09 ET | 39646 | 4.405 |
02:11 ET | 9172 | 4.4 |
02:13 ET | 9316 | 4.405 |
02:15 ET | 42403 | 4.38 |
02:18 ET | 44117 | 4.39 |
02:20 ET | 210909 | 4.365 |
02:22 ET | 14222 | 4.365 |
02:24 ET | 22221 | 4.365 |
02:26 ET | 3336 | 4.365 |
02:27 ET | 6075 | 4.365 |
02:29 ET | 3831 | 4.364 |
02:31 ET | 8081 | 4.36 |
02:33 ET | 16620 | 4.36 |
02:36 ET | 1804 | 4.355 |
02:38 ET | 2914 | 4.355 |
02:40 ET | 1700 | 4.36 |
02:42 ET | 9429 | 4.35 |
02:44 ET | 11957 | 4.355 |
02:45 ET | 1827 | 4.36 |
02:47 ET | 44422 | 4.34 |
02:49 ET | 7563 | 4.34 |
02:51 ET | 9545 | 4.345 |
02:54 ET | 1700 | 4.345 |
02:56 ET | 900 | 4.345 |
02:58 ET | 2600 | 4.345 |
03:00 ET | 17190 | 4.33 |
03:02 ET | 10667 | 4.325 |
03:03 ET | 6805 | 4.325 |
03:05 ET | 12251 | 4.325 |
03:07 ET | 20617 | 4.335 |
03:09 ET | 28547 | 4.325 |
03:12 ET | 9407 | 4.32 |
03:14 ET | 3593 | 4.32 |
03:16 ET | 13546 | 4.325 |
03:18 ET | 4980 | 4.33 |
03:20 ET | 10075 | 4.325 |
03:21 ET | 6109 | 4.33 |
03:23 ET | 3660 | 4.33 |
03:25 ET | 22102 | 4.32 |
03:27 ET | 7388 | 4.325 |
03:30 ET | 22789 | 4.315 |
03:32 ET | 39801 | 4.32 |
03:34 ET | 10227 | 4.31 |
03:36 ET | 17390 | 4.325 |
03:38 ET | 11925 | 4.33 |
03:39 ET | 8203 | 4.325 |
03:41 ET | 10877 | 4.325 |
03:43 ET | 18426 | 4.325 |
03:45 ET | 11137 | 4.325 |
03:48 ET | 75857 | 4.325 |
03:50 ET | 8921 | 4.325 |
03:52 ET | 50566 | 4.32 |
03:54 ET | 136600 | 4.315 |
03:56 ET | 69488 | 4.32 |
03:57 ET | 136015 | 4.315 |
03:59 ET | 684070 | 4.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.0x | --- |
Edgewise Therapeutics Inc | 2.6B | -17.4x | --- |
IDEAYA Biosciences Inc | 2.7B | -13.4x | --- |
Structure Therapeutics Inc | 2.5B | -18.9x | --- |
Immunitybio Inc | 2.5B | -3.6x | --- |
CG Oncology Inc | 2.4B | -30.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 1,949.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.